Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shanu Modi

Showing results (41-50 of 115) with videos related to

Pageof 12
Sort By:
The Oncologist|January 4, 2019
Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5-Year Follow-upRui Wang, Lillian M Smyth, Neil Iyengar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 25, 2012
Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancerSarat Chandarlapaty, Rita A Sakr, Dilip Giri, et al.
Research Square|May 10, 2023
Pruritus Related to Trastuzumab and Pertuzumab in HER2+ Breast Cancer PatientsStephanie Gu, Stephen Dusza, Elizabeth Quigley, et al.
Journal of Neuro-Oncology|June 5, 2025
Antibody drug conjugates in metastatic brain tumors: current landscape, therapeutic potential and challengesStephanie M Robert, Allison Toth, Sapir Lev, et al.
Japanese Journal of Clinical Oncology|January 17, 2024
Trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2-expressing salivary gland carcinoma: a pooled analysis of two phase I studiesShunji Takahashi, Hideaki Bando, Ichiro Kinoshita, et al.
Breast Cancer Research and Treatment|October 13, 2023
Pruritus related to trastuzumab and pertuzumab in HER2 + breast cancer patientsStephanie Gu, Stephen Dusza, Elizabeth Quigley, et al.
Breast Cancer Research and Treatment|April 2, 2005
A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancerShanu Modi, Andrew D Seidman, Maura Dickler, et al.
Breast (Edinburgh, Scotland)|June 9, 2026
New perspectives on endocrine therapy suitability for hormone receptor-positive metastatic breast cancer in clinical practiceHope S Rugo, Giuseppe Curigliano, David W Cescon, et al.
Cancer Prevention Research (Philadelphia, Pa.)|March 28, 2013
Increased levels of urinary PGE-M, a biomarker of inflammation, occur in association with obesity, aging, and lung metastases in patients with breast cancerPatrick G Morris, Xi Kathy Zhou, Ginger L Milne, et al.
Journal of Clinical Pharmacology|September 29, 2011
Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancerManish Gupta, Patricia M Lorusso, Bei Wang, et al.
Pageof 12

Showing results (41-50 of 115) with videos related to

Sort By:
Pageof 12
The Oncologist|January 4, 2019
Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5-Year Follow-upRui Wang, Lillian M Smyth, Neil Iyengar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 25, 2012
Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancerSarat Chandarlapaty, Rita A Sakr, Dilip Giri, et al.
Research Square|May 10, 2023
Pruritus Related to Trastuzumab and Pertuzumab in HER2+ Breast Cancer PatientsStephanie Gu, Stephen Dusza, Elizabeth Quigley, et al.
Journal of Neuro-Oncology|June 5, 2025
Antibody drug conjugates in metastatic brain tumors: current landscape, therapeutic potential and challengesStephanie M Robert, Allison Toth, Sapir Lev, et al.
Japanese Journal of Clinical Oncology|January 17, 2024
Trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2-expressing salivary gland carcinoma: a pooled analysis of two phase I studiesShunji Takahashi, Hideaki Bando, Ichiro Kinoshita, et al.
Breast Cancer Research and Treatment|October 13, 2023
Pruritus related to trastuzumab and pertuzumab in HER2 + breast cancer patientsStephanie Gu, Stephen Dusza, Elizabeth Quigley, et al.
Breast Cancer Research and Treatment|April 2, 2005
A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancerShanu Modi, Andrew D Seidman, Maura Dickler, et al.
Breast (Edinburgh, Scotland)|June 9, 2026
New perspectives on endocrine therapy suitability for hormone receptor-positive metastatic breast cancer in clinical practiceHope S Rugo, Giuseppe Curigliano, David W Cescon, et al.
Cancer Prevention Research (Philadelphia, Pa.)|March 28, 2013
Increased levels of urinary PGE-M, a biomarker of inflammation, occur in association with obesity, aging, and lung metastases in patients with breast cancerPatrick G Morris, Xi Kathy Zhou, Ginger L Milne, et al.
Journal of Clinical Pharmacology|September 29, 2011
Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancerManish Gupta, Patricia M Lorusso, Bei Wang, et al.
Pageof 12